Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 16,095 as of Wednesday, Nov. 27, 2013, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,757 issues advancing vs. 1,109 declining with 149 unchanged. The Health Services industry currently sits up 0.4% versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the industry include DaVita HealthCare Partners ( DVA), down 0.8%, and Boston Scientific ( BSX), down 0.4%. Top gainers within the industry include HCA Holdings ( HCA), up 1.2%, Intuitive Surgical ( ISRG), up 0.7%, St Jude Medical ( STJ), up 0.9%, Express Scripts ( ESRX), up 0.8% and Covidien ( COV), up 0.5%. TheStreet would like to highlight 4 stocks pushing the industry lower today: 4. Bio-Reference Labs ( BRLI) is one of the companies pushing the Health Services industry lower today. As of noon trading, Bio-Reference Labs is down $7.69 (-20.4%) to $30.04 on heavy volume. Thus far, 2.5 million shares of Bio-Reference Labs exchanged hands as compared to its average daily volume of 215,400 shares. The stock has ranged in price between $29.35-$34.99 after having opened the day at $34.83 as compared to the previous trading day's close of $37.73. Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. Bio-Reference Labs has a market cap of $1.0 billion and is part of the health care sector. The company has a P/E ratio of 21.8, above the S&P 500 P/E ratio of 17.7. Shares are up 31.8% year to date as of the close of trading on Tuesday. Currently there is 1 analyst that rates Bio-Reference Labs a buy, 1 analyst rates it a sell, and 1 rates it a hold. TheStreet Ratings rates Bio-Reference Labs as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bio-Reference Labs Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.